Neuroprotection in Glaucoma
- PMID: 27413504
- PMCID: PMC4926571
- DOI: 10.4103/2008-322X.183923
Neuroprotection in Glaucoma
Abstract
Glaucoma is a degenerative optic neuropathy characterized by retinal ganglion cell (RGC) loss and visual field defects. It is known that in some glaucoma patients, death of RGCs continues despite intraocular pressure (IOP) reduction. Neuroprotection in the field of glaucoma is defined as any treatment, independent of IOP reduction, which prevents RGC death. Glutamate antagonists, ginkgo biloba extract, neurotrophic factors, antioxidants, calcium channel blockers, brimonidine, glaucoma medications with blood regulatory effect and nitric oxide synthase inhibitors are among compounds with possible neuroprotective activity in preclinical studies. A few agents (such as brimonidine or memantine) with neuroprotective effects in experimental studies have advanced to clinical trials; however the results of clinical trials for these agents have not been conclusive. Nevertheless, lack of compelling clinical evidence has not prevented the off-label use of some of these compounds in glaucoma practice. Stem cell transplantation has been reported to halt experimental neurodegenerative disease processes in the absence of cell replacement. It has been hypothesized that transplantation of some types of stem cells activates multiple neuroprotective pathways via secretion of various factors. The advantage of this approach is a prolonged and targeted effect. Important concerns in this field include the secretion of unwanted harmful mediators, graft survival issues and tumorigenesis. Neuroprotection in glaucoma, pharmacologically or by stem cell transplantation, is an interesting subject waiting for broad and multidisciplinary collaborative studies to better clarify its role in clinical practice.
Keywords: Brimonidine; Ginkgo Biloba Extract; Glaucoma; Memantine; Neuroprotection; Stem Cell Transplantation.
Figures
Similar articles
-
Advances in Neuroprotection in Glaucoma: Pharmacological Strategies and Emerging Technologies.Pharmaceuticals (Basel). 2024 Sep 25;17(10):1261. doi: 10.3390/ph17101261. Pharmaceuticals (Basel). 2024. PMID: 39458902 Free PMC article. Review.
-
Retinal ganglion cell neuroprotection in a rat model of glaucoma following brimonidine, latanoprost or combined treatments.Exp Eye Res. 2008 May;86(5):798-806. doi: 10.1016/j.exer.2008.02.008. Epub 2008 Mar 4. Exp Eye Res. 2008. PMID: 18394603
-
Neuroprotection of retinal ganglion cells with GDNF-Loaded biodegradable microspheres in experimental glaucoma.Int J Ophthalmol. 2010;3(3):189-91. doi: 10.3980/j.issn.2222-3959.2010.03.01. Epub 2010 Sep 18. Int J Ophthalmol. 2010. PMID: 22553550 Free PMC article.
-
Alpha-2 adrenergic receptor agonists are neuroprotective in experimental models of glaucoma.Eur J Ophthalmol. 2001 Jul-Sep;11 Suppl 2:S30-5. doi: 10.1177/112067210101102s03. Eur J Ophthalmol. 2001. PMID: 11592528
-
Protection of retinal ganglion cells in glaucoma: Current status and future.Exp Eye Res. 2021 Apr;205:108506. doi: 10.1016/j.exer.2021.108506. Epub 2021 Feb 18. Exp Eye Res. 2021. PMID: 33609512 Review.
Cited by
-
Effect of oral citicoline therapy on retinal nerve fiber layer and ganglion cell-inner plexiform layer in patients with primary open angle glaucoma.Int J Ophthalmol. 2022 Mar 18;15(3):483-488. doi: 10.18240/ijo.2022.03.17. eCollection 2022. Int J Ophthalmol. 2022. PMID: 35310047 Free PMC article.
-
Neuroprotective effect of mesenchymal stem cell-derived extracellular vesicles on optic nerve injury in chronic ocular hypertension.Neural Regen Res. 2023 Oct;18(10):2301-2306. doi: 10.4103/1673-5374.369121. Neural Regen Res. 2023. PMID: 37056151 Free PMC article.
-
Rho Kinase Inhibitors as a Neuroprotective Pharmacological Intervention for the Treatment of Glaucoma.Cureus. 2022 Aug 26;14(8):e28445. doi: 10.7759/cureus.28445. eCollection 2022 Aug. Cureus. 2022. PMID: 36176819 Free PMC article. Review.
-
White matter alterations in glaucoma and monocular blindness differ outside the visual system.Sci Rep. 2021 Mar 25;11(1):6866. doi: 10.1038/s41598-021-85602-x. Sci Rep. 2021. PMID: 33767217 Free PMC article.
-
Neuroprotective Strategies for Retinal Ganglion Cell Degeneration: Current Status and Challenges Ahead.Int J Mol Sci. 2020 Mar 25;21(7):2262. doi: 10.3390/ijms21072262. Int J Mol Sci. 2020. PMID: 32218163 Free PMC article. Review.
References
-
- Gupta N, Weinreb RN. New definitions of glaucoma. Curr Opin Ophthalmol. 1997;8:38–41. - PubMed
-
- Brubaker RF. Delayed functional loss in glaucoma. LII Edward Jackson Memorial Lecture. Am J Ophthalmol. 1996;121:473–483. - PubMed
-
- Hattenhauer MG, Johnson DH, Ing HH, Herman DC, Hodge DO, Yawn BP, et al. The probability of blindness from open-angle glaucoma. Ophthalmology. 1998;105:2099–2104. - PubMed
-
- Sommer A, Katz J, Quigley HA, Miller NR, Robin AL, Richter RC, et al. Clinically detectable nerve fiber atrophy precedes the onset of glaucomatous field loss. Arch Ophthalmol. 1991;109:77–83. - PubMed
-
- Quigley HA, Addicks EM, Green WR, Maumenee AE. Optic nerve damage in human glaucoma. II. The site of injury and susceptibility to damage. Arch Ophthalmol. 1981;99:635–649. - PubMed